Filing Flows › Biogen (BIIB) › Q3 2026 › vs Q2 2026
Biogen (BIIB) Q3 2026 vs Q2 2026 (quarter over quarter)
Biogen's revenue rose $68.1M (+2%) from $2.7B in Q2 2026 to $2.8B in Q3 2026.
Biogen, Q3 2026: revenue $2.8B (+11% year over year), operating margin -0.3%, net loss $20.6M, operating cash flow $641M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $2.8B | $2.7B | $68.1M | +2% |
| Net loss | $20.6M | −$97.5M | $118M | — |
| Costs & expenses | $2.8B | $2.7B | $88.7M | +3% |
| Operating costs | $2.8B | $2.6B | $210M | +8% |
| Income tax | $11.6M | $34.9M | −$23.3M | -67% |
| Cost of revenue | $748M | $777M | −$28.5M | -4% |
| Research & development | $574M | $530M | $44.4M | +8% |
| SG&A | $752M | $710M | $42.3M | +6% |
| Other operating costs | $739M | $587M | $151M | +26% |
| Operating cash sources | $661M | $351M | $310M | +88% |
| Depreciation & amortization | $241M | $236M | $5.0M | +2% |
| Share-based compensation | $81.5M | $77.4M | $4.1M | +5% |
| Working capital & other | $339M | $37.9M | $301M | +794% |
| Net loss absorbed | $20.6M | −$97.5M | $118M | — |
| Operating cash flow | $641M | $449M | $192M | +43% |
Questions
How much did Biogen's revenue grow quarter over quarter in Q3 2026?
Biogen's revenue rose $68.1M (+2%) from $2.7B in Q2 2026 to $2.8B in Q3 2026.